RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL

Kate E. Lawlor(Walter and Eliza Hall Institute of Medical Research), Nufail Khan(Walter and Eliza Hall Institute of Medical Research), Alison Mildenhall(Walter and Eliza Hall Institute of Medical Research), Motti Gerlic(Tel Aviv University), Ben A. Croker(Boston Children's Hospital), Akshay A. D’Cruz(Boston Children's Hospital), Cathrine Hall(Walter and Eliza Hall Institute of Medical Research), Sukhdeep K. Spall(Walter and Eliza Hall Institute of Medical Research), Holly Anderton(Walter and Eliza Hall Institute of Medical Research), Seth L. Masters(The University of Melbourne), Maryam Rashidi(Walter and Eliza Hall Institute of Medical Research), Ian P. Wicks(The University of Melbourne), Warren S. Alexander(The University of Melbourne), Yasuhiro Mitsuuchi(TetraLogic Pharmaceuticals (United States)), Christopher A. Benetatos(TetraLogic Pharmaceuticals (United States)), Stephen M. Condon(TetraLogic Pharmaceuticals (United States)), W. Wei‐Lynn Wong(University of Zurich), John Silke(The University of Melbourne), David L. Vaux(The University of Melbourne), James E. Vince(The University of Melbourne)
Nature Communications
February 18, 2015
Cited by 638Open Access
Full Text

Abstract

RIPK3 and its substrate MLKL are essential for necroptosis, a lytic cell death proposed to cause inflammation via the release of intracellular molecules. Whether and how RIPK3 might drive inflammation in a manner independent of MLKL and cell lysis remains unclear. Here we show that following LPS treatment, or LPS-induced necroptosis, the TLR adaptor protein TRIF and inhibitor of apoptosis proteins (IAPs: X-linked IAP, cellular IAP1 and IAP2) regulate RIPK3 and MLKL ubiquitylation. Hence, when IAPs are absent, LPS triggers RIPK3 to activate caspase-8, promoting apoptosis and NLRP3-caspase-1 activation, independent of RIPK3 kinase activity and MLKL. In contrast, in the absence of both IAPs and caspase-8, RIPK3 kinase activity and MLKL are essential for TLR-induced NLRP3 activation. Consistent with in vitro experiments, interleukin-1 (IL-1)-dependent autoantibody-mediated arthritis is exacerbated in mice lacking IAPs, and is reduced by deletion of RIPK3, but not MLKL. Therefore RIPK3 can promote NLRP3 inflammasome and IL-1β inflammatory responses independent of MLKL and necroptotic cell death.


Related Papers

No related papers found

Powered by citation graph analysis